Search research articles
Contact Us
Filters
Showing results (411-420 of 584) with videos related to
Page
of 59
Sort By:
American Journal of Hematology
|
July 4, 2014
Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia
Gautam Borthakur, Jorge E Cortes, Elihu E Estey, et al.
Leukemia & Lymphoma
|
November 26, 2019
Consolidation outcomes in CPX-351 versus cytarabine/daunorubicin-treated older patients with high-risk/secondary acute myeloid leukemia
Jonathan E Kolitz, Stephen A Strickland, Jorge E Cortes, et al.
Peerj
|
June 28, 2021
HPV molecular detection from urine versus cervical samples: an alternative for HPV screening in indigenous populations
Francisco I Torres-Rojas, Miguel A Mendoza-Catalán, Luz Del C Alarcón-Romero, et al.
Cancers
|
June 28, 2023
Clinical Utility of Optical Genome Mapping and 523-Gene Next Generation Sequencing Panel for Comprehensive Evaluation of Myeloid Cancers
Nikhil Shri Sahajpal, Ashis K Mondal, Harmanpreet Singh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 6, 2011
Dasatinib-responsive mast cell neoplasms as initial presentation of chronic myelogenous leukemia in blast phase
Carlos E Vigil, Sa A Wang, Jorge E Cortes, et al.
American Journal of Hematology
|
August 6, 2013
Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors
Lorenzo Falchi, Hagop M Kantarjian, Xuemei Wang, et al.
Journal of Hematology & Oncology
|
June 16, 2021
Impact of frontline treatment approach on outcomes of myeloid blast phase CML
Kapil Saxena, Elias Jabbour, Ghayas Issa, et al.
Cancer
|
December 22, 2017
Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase
Koji Sasaki, Hagop Kantarjian, Susan O'Brien, et al.
Hematological Oncology
|
June 28, 2020
Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies
Tariq I Mughal, Naveen Pemmaraju, Bethan Psaila, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 2, 2003
Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia
Francis J Giles, Hagop M Kantarjian, Jorge E Cortes, et al.
Page
of 59
Search research articles
Search
Showing results (411-420 of 584) with videos related to
Sort By:
Page
of 59
American Journal of Hematology
|
July 4, 2014
Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia
Gautam Borthakur, Jorge E Cortes, Elihu E Estey, et al.
Leukemia & Lymphoma
|
November 26, 2019
Consolidation outcomes in CPX-351 versus cytarabine/daunorubicin-treated older patients with high-risk/secondary acute myeloid leukemia
Jonathan E Kolitz, Stephen A Strickland, Jorge E Cortes, et al.
Peerj
|
June 28, 2021
HPV molecular detection from urine versus cervical samples: an alternative for HPV screening in indigenous populations
Francisco I Torres-Rojas, Miguel A Mendoza-Catalán, Luz Del C Alarcón-Romero, et al.
Cancers
|
June 28, 2023
Clinical Utility of Optical Genome Mapping and 523-Gene Next Generation Sequencing Panel for Comprehensive Evaluation of Myeloid Cancers
Nikhil Shri Sahajpal, Ashis K Mondal, Harmanpreet Singh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 6, 2011
Dasatinib-responsive mast cell neoplasms as initial presentation of chronic myelogenous leukemia in blast phase
Carlos E Vigil, Sa A Wang, Jorge E Cortes, et al.
American Journal of Hematology
|
August 6, 2013
Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors
Lorenzo Falchi, Hagop M Kantarjian, Xuemei Wang, et al.
Journal of Hematology & Oncology
|
June 16, 2021
Impact of frontline treatment approach on outcomes of myeloid blast phase CML
Kapil Saxena, Elias Jabbour, Ghayas Issa, et al.
Cancer
|
December 22, 2017
Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase
Koji Sasaki, Hagop Kantarjian, Susan O'Brien, et al.
Hematological Oncology
|
June 28, 2020
Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies
Tariq I Mughal, Naveen Pemmaraju, Bethan Psaila, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 2, 2003
Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia
Francis J Giles, Hagop M Kantarjian, Jorge E Cortes, et al.
Page
of 59